Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Point72 Europe London LLP

Point72 Europe London LLP decreased its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 29.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,420 shares of the company’s stock after selling 13,413 shares during the quarter. Point72 Europe London LLP owned about 0.05% of Structure Therapeutics worth $852,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of GPCR. Virtus ETF Advisers LLC raised its holdings in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Structure Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company’s stock worth $1,240,000 after purchasing an additional 480 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock worth $311,000 after purchasing an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company’s stock worth $201,000 after acquiring an additional 843 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $24.43 on Friday. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The stock has a market cap of $1.40 billion, a PE ratio of -33.01 and a beta of -1.69. The stock has a 50-day moving average of $21.09 and a 200-day moving average of $26.64.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GPCR. HC Wainwright decreased their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a report on Monday. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a “buy” rating and a $60.00 price target on the stock. Finally, William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.